GENinCode PLC on Wednesday said it will collaborate with MedStar Health for the use of its coronary heart disease diagnostic test.
The biotechnology company focused on prevention of cardiovascular disease said its Cardio inCode-Score, or CIC-SCORE, test will be used alongside the standard American College of Cardiology Atherosclerotic Cardiovascular Disease risk calculator to identify patients suffering from CHD.
GENinCode’s test is a patented polygenic test used to assess the risk of CHD.
MedStar is a Columbia, South Carolina-based healthcare organisation operating 10 hospitals in the Baltimore-Washington metropolitan area of the US.
Meanwhile, MedStar will provide feedback on the clinical use of the CIC-SCORE test.
GENinCode Chief Executive Officer Matthew Walls said: ‘We are pleased to announce our first major US clinical collaboration with MedStar, which will focus on use of CIC-SCORE to identify patients at high risk of heart disease, the largest cause of death in the US. We look forward to working closely with the MedStar team to identify patients at risk, inform personalised treatment and prevent coronary heart disease.’
Shares in GENinCode were up 3.8% at 12.20 pence each in London on Wednesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
